Application of prmt7 as a target in preparation of a drug for inhibiting proliferation of subgroup j avian leukosis virus

CN122643448APending Publication Date: 2026-08-28FOSHAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611149931.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-31
Publication Date
2026-08-28

AI Technical Summary

Technical Problem

[0005]为了克服现有技术的不足,本发明的目的在于提供PRMT7作为靶点在制备抑制J亚群禽白血病病毒增殖药物中的应用,并提供PRMT7基因多态性位点作为分子标记在评估家禽对J亚群禽白血病病毒抗性中的应用,以解决现有技术中缺乏针对ALV-J感染的有效分子调控靶点及抗病遗传标记的问题

Benefits of technology

[0019]1. This invention reveals the immunomodulatory role of PRMT7 in the ALV-J infection process and confirms that inhibiting PRMT7 expression can enhance the activity of type I interferon-related pathways, thereby inhibiting viral replication.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122643448A_ABST
    Figure CN122643448A_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of biological genetic engineering, and relates to application of PRMT7 as a target point in preparation of a medicine for inhibiting proliferation of subgroup J avian leukemia virus, and application of a PRMT7 gene polymorphism site as a molecular marker for evaluating resistance of poultry to subgroup J avian leukemia virus. Research shows that PRMT7 is involved in immune regulation of a host to infection of subgroup J avian leukemia virus, and inhibition of PRMT7 expression can enhance activity of a type I interferon related path and reduce a virus replication level. Further, a plurality of nucleotide polymorphism sites in the PRMT7 gene are screened to obtain a significant correlation with an ALV-J related phenotype, and the related phenotype includes a pancreas tissue index, a spleen tissue index, a bursa of fabricius tissue index, an IL-6 level and an IFN alpha level. The application provides a new technical scheme for prevention and control of subgroup J avian leukemia virus, development of an antiviral target point and poultry disease resistance molecular breeding.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of bioengineering technology, specifically to the application of PRMT7 as a target in the preparation of drugs that inhibit the proliferation of J subgroup avian leukosis virus. Background Technology

[0002] Avian leukosis virus (ALV) is an important retrovirus that can cause tumors and immunosuppression in birds. Among them, subgroup J avian leukosis virus (ALV-J) is one of the most widespread and harmful subgroups in broiler and local chicken flocks. ALV-J infection can cause various neoplastic diseases such as myeloma and hemangioma, while also leading to immunosuppression, growth retardation, and decreased production performance. Currently, there are no safe and effective vaccines or specific treatments for ALV-J infection. Control in production mainly relies on traditional methods such as flock purification and culling of positive individuals, but these methods are time-consuming and costly. Therefore, there is an urgent need to explore new antiviral regulatory targets at the molecular level.

[0003] Type I interferon (IFN I) is an important natural immune factor for the body to defend against viral infection. When a virus invades a host cell, the cell recognizes the viral nucleic acid through pattern recognition receptors and activates downstream signaling cascades, thereby inducing the expression of interferons such as IFNα. IFNα has a clear inhibitory effect on ALV-J replication. Elucidating the regulatory mechanism of IFNα is of great significance for discovering new antiviral targets.

[0004] The protein arginine methyltransferase (PRMT) family is a class of important epigenetic regulatory enzymes that catalyze methylation of protein arginine residues, playing crucial roles in various biological processes such as transcriptional regulation, RNA processing, signal transduction, and immune responses. PRMT7, a type III PRMT member, primarily catalyzes monomethylation. Currently, systematic research on the function and molecular mechanisms of PRMT7 in avian virus infections, particularly ALV-J infection, is lacking. Therefore, discovering the role of PRMT7 in regulating the type I interferon signaling pathway and ALV-J replication is of great significance for developing new anti-avian leukosis virus technologies. Summary of the Invention

[0005] To overcome the shortcomings of the prior art, the present invention aims to provide the application of PRMT7 as a target in the preparation of drugs that inhibit the proliferation of avian leukosis J subgroup virus, and to provide the application of PRMT7 gene polymorphism sites as molecular markers in the evaluation of poultry resistance to avian leukosis J subgroup virus, so as to solve the problem of the lack of effective molecular regulatory targets and disease resistance genetic markers for ALV-J infection in the prior art.

[0006] The protein arginine methyltransferase (PRMT) family is a class of important epigenetic regulatory enzymes that catalyze methylation of protein arginine residues, playing crucial roles in various biological processes such as transcriptional regulation, RNA processing, signal transduction, and immune responses. PRMT7, a type III PRMT member, primarily catalyzes monomethylation. Currently, systematic research on the function and molecular mechanisms of PRMT7 in avian virus infections, particularly ALV-J infection, is lacking. Therefore, discovering the role of PRMT7 in regulating the type I interferon signaling pathway and ALV-J replication is of great significance for developing new anti-avian leukosis virus technologies.

[0007] This invention reveals through experiments that PRMT7 participates in the immune regulation process of ALV-J infection in chicken hosts. Inhibition or knockdown of PRMT7 expression activates type I interferon and its related pathways, leading to a decrease in viral replication levels, indicating that PRMT7 can serve as an important molecular target for inhibiting ALV-J replication.

[0008] To achieve the above objectives, the technical solution adopted by the present invention is as follows: the application of PRMT7 as a target in the preparation of drugs that inhibit the proliferation of J subgroup avian leukosis virus, and the use of PRMT7 as an inhibitor to inhibit the replication of J subgroup avian leukosis virus.

[0009] In a preferred embodiment of the application described in this invention, the PRMT7 inhibitor is used to downregulate the expression level of the PRMT7 gene and / or protein in host cells.

[0010] In a preferred embodiment of the application described in this invention, the PRMT7 inhibitor is selected from one or more of siRNA, shRNA, antisense oligonucleotides, sgRNA, antibodies, or small molecule compounds.

[0011] In a preferred embodiment of the application described in this invention, PRMT7 is an inhibitor of the target site that inhibits the replication of subgroup J avian leukosis virus by regulating the type I interferon-related signaling pathway.

[0012] In a preferred embodiment of the application described in this invention, the type I interferon is IFNα.

[0013] Furthermore, this invention provides the application of PRMT7 gene polymorphism sites as molecular markers in assessing the resistance of poultry to subgroup J avian leukosis virus. By detecting the genotype of one or more nucleotide polymorphism sites in the PRMT7 gene of individual poultry, the individual's disease resistance can be assessed and used for screening resistant individuals, evaluating germplasm resources, and molecular marker-assisted breeding.

[0014] The nucleotide polymorphism sites include NC052542.1:266418_A>G, NC052542.1:264401_G>T, NC052542.1:267112_T>C, NC052542.1:272801_C>T, NC052542.1:263594_C>T, NC052542.1:263686_T>G, and NC052542.1:263687_G. One or more of the following: >A, NC052542.1:269958_A>G, NC052542.1:269980_C>T, NC052542.1:270000_A>T, NC052542.1:271187_T>C, NC052542.1:265979_A>G, NC052542.1:269946_T>C, and NC052542.1:270092_A>G.

[0015] In a preferred embodiment of the application described in this invention, the PRMT7 gene polymorphic site, as a molecular marker, is associated with one or more of the following disease-resistance phenotypes: pancreatic tissue index, spleen tissue index, bursal tissue index, IL-6 level, and IFNα level. These sites are significantly associated with disease-resistance phenotypes such as pancreatic tissue index, spleen tissue index, bursal tissue index, IL-6 level, and IFNα level, and can serve as candidate molecular markers for assessing poultry resistance to ALV-J.

[0016] As a preferred embodiment of the application described in this invention, the genotype detection method is PCR amplification, sequencing, SNP genotyping, or microarray detection.

[0017] As a preferred embodiment of the application described in this invention, the PRMT7 gene polymorphism site is used as a molecular marker for screening disease-resistant individuals, evaluating germplasm resources, or molecular marker-assisted breeding.

[0018] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0019] 1. This invention reveals the immunomodulatory role of PRMT7 in the ALV-J infection process and confirms that inhibiting PRMT7 expression can enhance the activity of type I interferon-related pathways, thereby inhibiting viral replication.

[0020] 2. This invention provides the application of PRMT7 as an anti-ALV-J functional target, providing a new molecular basis for antiviral drug screening and development.

[0021] 3. This invention screened and obtained multiple nucleotide polymorphism sites in the PRMT7 gene that are significantly associated with anti-ALV-J phenotypes. The associated phenotypes include pancreatic tissue index, spleen tissue index, bursa of Fabricius tissue index, IL-6 level, and IFNα level.

[0022] 4. This invention provides an applicable genetic marker basis for molecular breeding of poultry resistant to ALV-J. Attached Figure Description

[0023] Figure 1 shows the relative expression level of PRMT7 in immune tissues after ALV-J infection. All values ​​are expressed as mean ± SEM (n=3), and (*) indicates statistical significance (P<0.05).

[0024] Figure 2 shows the relative expression level of PRMT7 in ALV-J secondary infected cells after PRMT7 overexpression. All values ​​are expressed as mean ± SEM (n=3), and (*) indicates statistical significance (P<0.05).

[0025] Figure 3 shows the expression level of PRMT7 protein in ALV-J cells after PRMT7 overexpression.

[0026] Figure 4 shows the relative expression levels of IFNα after PRMT7 overexpression or interference; all values ​​are expressed as mean ± SEM (n=3), and (*) indicates statistical significance (P<0.05).

[0027] Figure 5 shows the relative expression levels of TRIF, TLR3, and TRAF3 after PRMT7 overexpression or interference. All values ​​are expressed as mean ± SEM (n=3), and (*) indicates statistical significance (P<0.05). Detailed Implementation

[0028] To better illustrate the purpose, technical solution, and advantages of this invention, the invention will be further described below with reference to specific drawings and embodiments. Unless otherwise specified, the experimental methods used in the embodiments are conventional methods, and the materials and reagents used are commercially available unless otherwise specified.

[0029] To explain the technical solution of the present invention more clearly and in more detail, some embodiments are provided below for further illustration.

[0030] Example 1: Expression of the PRMT7 gene in immune tissues of chickens infected with ALV-J

[0031] 1. Experimental materials

[0032] One-day-old healthy Qingyuan Ma chickens, ALV-J virus, TRIzol reagent, reverse transcription kit, and real-time PCR reagent.

[0033] 2. Experimental Methods

[0034] The infected group was injected intraperitoneally with 100 units of virus, while the control group was injected with an equal volume of PBS. Thymus, spleen, and bursa of Fabricius tissues were collected from both groups at 15 days of age. RNA was extracted from the tissues after flash freezing in liquid nitrogen, and after reverse transcription, PRMT7 and the internal reference gene GAPDH were detected by quantitative real-time PCR.

[0035] 3. Experimental Results

[0036] The relative expression level of PRMT7 in the infection group was higher than that in the control group, and there were significant differences in the spleen and bursa of Fabricius between the two groups (P<0.05).

[0037] Example 2: Cloning of the chicken PRMT7 gene and construction of overexpression plasmids

[0038] 1. Experimental materials

[0039] Cells: Chicken embryo fibroblast cell line DF-1

[0040] Reagents: TRIzol reagent, reverse transcription kit, high-fidelity PCR enzyme, restriction endonuclease, T4 DNA ligase, plasmid extraction kit

[0041] Vector: eukaryotic overexpression vector pcDNA3.1

[0042] 2. Experimental Methods

[0043] (1) Total RNA extraction and cDNA synthesis

[0044] DF-1 cells in good growth condition were used to extract total RNA according to the TRIzol instructions. RNA integrity was detected by agarose gel electrophoresis. cDNA was synthesized using the total RNA as a template and stored at -20℃ for later use.

[0045] (2) PCR amplification of the PRMT7 gene

[0046] Specific primers were designed based on the chicken PRMT7 gene sequence published by NCBI. PCR amplification was performed using cDNA as a template. The reaction conditions were: 95℃ pre-denaturation for 5 min; 95℃ denaturation for 30 s, 58℃ annealing for 30 s, 72℃ extension for 2 min, for a total of 35 cycles; and 72℃ final extension for 10 min.

[0047] (3) Construction and validation of recombinant plasmids

[0048] After PCR product was purified by gel extraction, it was double-digested with restriction endonucleases and ligated into the pcDNA3.1 vector, which was also double-digested. The ligation was then performed on competent E. coli cells. Single colonies were picked, and plasmids were extracted for PCR and double-enzyme digestion identification. Positive recombinant plasmids were sent for sequencing to confirm that the sequence and reading frame were completely correct, thus obtaining the pcDNA3.1-PRMT7 overexpression plasmid.

[0049] 3. Experimental Results

[0050] The complete coding region of the chicken PRMT7 gene (SEQ ID NO: 1) was successfully amplified. The recombinant plasmid was identified and sequenced correctly and can be used for subsequent cell transfection experiments.

[0051] Example 3: Design and Synthesis of PRMT7 Interference Fragment (siRNA)

[0052] 1. Experimental Methods

[0053] Three specific siRNA sequences and one negative control siRNA sequence were designed targeting the coding region of the chicken PRMT7 gene and were chemically synthesized by a biotechnology company.

[0054] The interference efficiency of siRNA on the PRMT7 gene in DF-1 cells was detected by qPCR, and the sequence with the highest interference efficiency was screened for subsequent experiments.

[0055] 2. Experimental Results

[0056] A specific siRNA sequence (SEQ ID NO: 2) that can significantly inhibit intracellular PRMT7 expression was obtained through screening.

[0057] Example 4: Cell transfection, ALV-J infection, and sample collection

[0058] 1. Experimental materials

[0059] Virus: Avian leukosis virus subgroup J (ALV-J)

[0060] Culture conditions: 37℃, 5% CO2 incubator, DMEM / F12 1:1 medium + 10% fetal bovine serum

[0061] 2. Experimental Methods

[0062] (1) Cell inoculation

[0063] DF-1 cells were seeded into 6-well plates and cultured to 70%–80% confluence.

[0064] (2) Cell transfection

[0065] The study was divided into 7 groups: empty vector control group (NC), empty vector + ALV-J virus group (NC-A), PRMT7 overexpression group (P), PRMT7 overexpression + ALV-J virus group (PA); siRNA control group (si-NC) and PRMT7 interference group (si-P). The overexpression plasmid / siRNA was transfected according to the transfection reagent instructions, and the cells were cultured for 24 h after transfection.

[0066] (3) Viral infection

[0067] Discard the cell culture medium, wash once with PBS, add an appropriate amount of ALV-J virus solution, incubate at 37℃ for 2 h, discard the virus solution, replace with maintenance medium containing 2% fetal bovine serum, and continue culturing.

[0068] (4) Sample collection

[0069] Cell pellets were collected at 24 h and 48 h post-infection for RNA and protein extraction.

[0070] Example 5: Effect of ALV-J on PRMT7 expression

[0071] 1. Experimental Methods

[0072] (1) qPCR detection of PRMT7 expression

[0073] Total RNA was extracted from cells in each group using Trizol, and cDNA was synthesized by reverse transcription; GAPDH was used as an internal reference gene, and 2... ^(-ΔΔCt) The relative expression levels of the PRMT7 gene in the NC, NC-A, P, and PA groups were detected by a method.

[0074] (2) Western blot detection of PRMT7 protein expression

[0075] Total protein was extracted from cells in the NC, NC-A, P, and PA groups, and protein concentration was determined by the BCA method. SDS-PAGE electrophoresis was performed, and the protein was transferred to a PVDF membrane and blocked with 5% skim milk. PRMT7 specific primary antibody and GAPDH internal control primary antibody were added and incubated overnight at 4°C. Secondary antibody was incubated at room temperature for 1 h, and ECL chemiluminescence was used for imaging.

[0076] 2. Experimental Results

[0077] After transfection with the PRMT7 overexpression plasmid, the expression level of PRMT7 in cells was significantly upregulated (P<0.05). Following ALV-J virus infection, PRMT7 expression was again highly elevated in the PRMT7 overexpression plasmid treatment group (P<0.05). The results indicate that ( Figure 2 , Figure 3 ).

[0078] 3. Conclusion

[0079] PRMT7 is involved in ALV-J infection.

[0080] Example 6: Regulation of Type I Interferon (IFNα) Expression by PRMT7

[0081] 1. Experimental Methods

[0082] The expression of the IFNα gene in four cell groups (NC, P, si-P, and si-NC) was detected by qPCR.

[0083] 2. Experimental Results

[0084] ALV-J induces high expression of IFNα, and IFNα expression is significantly downregulated after PRMT7 overexpression (P<0.05). IFNα expression is significantly upregulated after PRMT7 interference (P<0.05). Figure 4 ).

[0085] 3. Conclusion

[0086] This indicates that PRMT7 negatively regulates the type I interferon signaling pathway, and inhibiting PRMT7 can activate the host's antiviral innate immunity.

[0087] Example 7: Verification of the molecular mechanism by which PRMT7 regulates IFNα expression

[0088] 1. Experimental Methods

[0089] qPCR was used to detect the mRNA expression levels of key molecules in four pathways: NC, P, si-P, and si-NC: TRIF, TLR3, and TRAF3.

[0090] 2. Experimental Results

[0091] After PRMT7 overexpression, TRIF expression showed no significant change, TLR3 expression was significantly upregulated (P<0.05), and TRAF3 expression was significantly downregulated (P<0.05). After PRMT7 interference, TRIF expression was significantly downregulated (P<0.05), TLR3 expression was significantly upregulated (P<0.05), and TRAF3 expression was significantly downregulated (P<0.05) (see Figure 5).

[0092] 3. Conclusion

[0093] PRMT7 regulates IFNα expression by modulating the TRIF signaling pathway, which controls type I interferon synthesis. Inhibiting PRMT7 expression can significantly enhance the host's antiviral immune response; therefore, PRMT7 can serve as an important molecular target for combating avian leukosis virus.

[0094] Example 8: Screening of PRMT7 gene polymorphism sites and their application as molecular markers against ALV-J

[0095] 1. Experimental Materials and Methods

[0096] The disease resistance-related phenotypes of the infected population in Example 1 were recorded and statistically analyzed. Blood samples were collected, and genomic DNA was extracted for genome resequencing. The sequencing data were analyzed to obtain information on all SNP mutations in the genome. All mutation sites in the PRMT7 gene sequence were identified, genotypes were analyzed, and genotype frequencies were calculated. Association analysis was performed between the obtained genotype results and the disease resistance-related phenotypes to screen candidate molecular markers associated with disease resistance.

[0097] 2. Experimental Results

[0098] Table 1 shows that multiple nucleotide polymorphisms in the PRMT7 gene were significantly associated with different disease resistance-related phenotypes. Specifically, NC052542.1:266418_A>G, NC052542.1:264401_G>T, and NC052542.1:267112_T>C were significantly associated with pancreatic tissue index; NC052542.1:272801_C>T was significantly associated with spleen tissue index; and NC052542.1:263594_C>T, NC052542.1:263686_T>G, NC052542.1:263687_G>A, NC052542.1:269958_A>G, and NC052542.1:269... 980_C>T, NC052542.1:270000_A>T, and NC052542.1:265979_A>G were significantly correlated with IL-6 levels; NC052542.1:269958_A>G, NC052542.1:269980_C>T, NC052542.1:270000_A>T, and NC052542.1:271187_T>C were significantly correlated with the bursa of Fabricius tissue index; NC052542.1:269946_T>C and NC052542.1:270092_A>G were significantly correlated with IFNα levels.

[0099] 3. Conclusion

[0100] The above results indicate that PRMT7 can not only serve as a functional target for inhibiting ALV-J replication, but also as a molecular marker for assessing poultry's resistance to ALV-J, and has application value in screening disease-resistant individuals and molecular marker-assisted breeding.

[0101] Table 1. Screening results of molecular markers related to ALV-J resistance in the PRMT7 gene.

[0102] .

Claims

1. The application of PRMT7 as a target in the preparation of drugs to inhibit the proliferation of subgroup J avian leukosis virus, characterized in that, Inhibitors targeting PRMT7 were used to suppress the replication of subgroup J avian leukosis virus.

2. The application as described in claim 1, characterized in that, The inhibitor is used to downregulate the expression level of the PRMT7 gene and / or protein in host cells.

3. The application as described in claim 1 or 2, characterized in that, The inhibitor is selected from one or more of siRNA, shRNA, antisense oligonucleotides, sgRNA, antibodies, or small molecule compounds.

4. The application as described in claim 3, characterized in that, The inhibitor suppresses the replication of subgroup J avian leukosis virus by modulating the type I interferon-associated signaling pathway.

5. The application as described in claim 4, characterized in that, The type I interferon is IFNα.

6. The application of the PRMT7 gene polymorphism site as a molecular marker in assessing poultry resistance to subgroup J avian leukosis virus, characterized in that... Genotypes of one or more nucleotide polymorphism sites in the PRMT7 gene of poultry individuals are detected, and the ability of poultry individuals to resist J subgroup avian leukosis virus is assessed or screened based on the genotypes.

7. The application as described in claim 6, characterized in that, The nucleotide polymorphism sites include NC052542.1:266418_A>G, NC052542.1:264401_G>T, NC052542.1:267112_T>C, NC052542.1:272801_C>T, NC052542.1:263594_C>T, NC052542.1:263686_T>G, and NC052542.1:263687_G. One or more of the following: >A, NC052542.1:269958_A>G, NC052542.1:269980_C>T, NC052542.1:270000_A>T, NC052542.1:271187_T>C, NC052542.1:265979_A>G, NC052542.1:269946_T>C, and NC052542.1:270092_A>G.

8. The application as described in claim 6, characterized in that, The disease-resistance-related phenotypes associated with the PRMT7 gene polymorphism site molecular markers include one or more of the following: pancreatic tissue index, spleen tissue index, bursa of Fabricius tissue index, IL-6 level, and IFNα level.

9. The application as described in claim 6, characterized in that, The method for detecting the genotype of one or more nucleotide polymorphism sites in the PRMT7 gene of poultry individuals is PCR amplification, sequencing, SNP typing, or microarray detection.

10. The application as described in any one of claims 6-9, characterized in that, The PRMT7 gene polymorphism site molecular markers are used for screening disease-resistant individuals, evaluating germplasm resources, or marker-assisted breeding.